On February 11, 2025, the Food and Drug Administration authorized the use of brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in conjunction with lenalidomide and a rituximab produc...
On January 21, 2025, the Food and Drug Administration sanctioned treosulfan (Grafapex, medac GmbH), an alkylating agent, in conjunction with fludarabine as a preparative regimen for allogeneic hematop...
On November 15, 2024, the Food and Drug Administration sanctioned revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia characterized by a ...
IntroductionHematological malignancies, such as leukemias, lymphomas, and multiple myeloma, are a heterogeneous group of cancers that arise in the bone marrow and lymphatic system. Conventional trea...
IntroductionBlood cancers, also known as hematologic malignancies, include leukemia, lymphoma, and multiple myeloma. These cancers have their origins in either bone marrow or the lymphatic system an...
Introduction CAR T cell therapy has been a game-changer in the treatment of certain lymphomas, more so in patients relapsing or refractory to conventional therapies. This has been quite successful in...
Introduction Chronic lymphocytic leukemia (CLL) is a long-lasting condition where mature B lymphocytes, which have encountered antigens before, become cancerous. This leads to the buildup of malignan...
Introduction In the ever-evolving realm of oncological treatment, scientists persistently seek out unconventional targets that can amplify the effectiveness of interventions while mitigating unwanted...
March 2024: Ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) has received fast approval from the Food and Drug Administration for use in combination with chemotherapy in adult patients who hav...
6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or refractory CD22-positive B-cell precursor acute...